Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Orphazyme A/S: Financial calendar

Orphazyme A/S
Posted on: 16 Nov 17
Company announcement Orphazyme A/S
No. 6/2017Ole Maaløes Vej 3
 DK-2200 Copenhagen N
  
  www.orphazyme.com
 Company Registration No. 32266355
  
 16 November 2017

Orphazyme A/S ("Orphazyme" or the "Company") expects to publish financial reports according to the following schedule:

Deadline for submitting shareholder proposals to the Annual General Meeting Wednesday 28 February 2018
Annual report for the full year ending 31 December 2017 Thursday 15 March 2018
Annual General Meeting 2018Thursday 12 April 2018
Interim report for the period ending 30 June 2018Tuesday 28 August 2018

The financial reports will upon their release be available at the Company's website, www.orphazyme.com , where information relating to Orphazyme's Annual General Meeting 2018 will also be available in due course prior to the meeting.  

For additional information, please contact   
Orphazyme  
Anders Vadsholt, CFO+45 28 98 90 55

About Orphazyme

Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. The Company was founded in 2009 based on early scientific discovery in heat shock proteins ("HSPs"). Since inception, the Company has translated scientific discovery into a late stage clinical development programme. The Company is headquartered in Copenhagen and currently has 30 employees.

The Company focuses on severe and mostly fatal diseases with a high unmet need, and with a particularly strong commitment to neuromuscular diseases and a group of severe genetic diseases called lysosomal storage diseases. The Company plans to pursue development of its lead candidate through to registration in the EU and the United States after which launch and commercialisation is expected to be undertaken by the Company.

The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis ("sIBM") and Amyotrophic Lateral Sclerosis ("ALS"), and two lysosomal storage diseases, Niemann Pick type C ("NPC") and Gaucher disease.

Orphazyme A/S - Financial calendar


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Orphazyme A/S via GlobeNewswire
HUG#2150187
GlobeNewswire
globenewswire.com

Last updated on: 17/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.